Carcinoma in situ of ureter

disease

On this page

Also known as carcinoma in situ of the ureterstage 0 ureter carcinomastage 0is carcinoma of the ureterstage 0is carcinoma of ureterstage 0is ureter cancerstage 0is ureter cancer aJCC v7stage 0is ureter carcinomastage 0is ureter urothelial cancerstage 0is ureter urothelial carcinomastage 0is ureter urothelial carcinoma aJCC v7stage 0is ureteral carcinomaureter cancer stage 0isureter carcinoma in situureter in situ carcinomaureteral carcinoma in situ

Summary

Carcinoma in situ of ureter (MONDO:0021284) is a cancer and 2 clinical trials. Top therapeutic interventions include erlotinib hydrochloride. A subtype of in situ carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Classification: Cancer
Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	carcinoma in situ of ureter
Mondo ID	MONDO:0021284
NCIT	C4529
SNOMED CT	92782006
UMLS	C4721448
MedGen	1660901
Anatomy (UBERON)	UBERON:0000056
Is cancer (heuristic)	yes

Also known as: carcinoma in situ of the ureter · carcinoma in situ of ureter · stage 0 ureter carcinoma · stage 0is carcinoma of the ureter · stage 0is carcinoma of ureter · stage 0is ureter cancer · stage 0is ureter cancer aJCC v7 · stage 0is ureter carcinoma · stage 0is ureter urothelial cancer · stage 0is ureter urothelial carcinoma · stage 0is ureter urothelial carcinoma aJCC v7 · stage 0is ureteral carcinoma · ureter cancer stage 0is · ureter carcinoma in situ · ureter in situ carcinoma · ureteral carcinoma in situ

Disease family

This is a subtype of in situ carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › in situ carcinoma › carcinoma in situ of ureter

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00749892	PHASE2	COMPLETED	Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
NCT04398368	PHASE2	TERMINATED	Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ERLOTINIB HYDROCHLORIDE	4	1

Drugs: Erlotinib